Skip to main content
main-content

Canagliflozin

29-09-2021 | EASD 2021 | Conference coverage | News

TriMaster supports precision medicine strategy for type 2 diabetes treatment intensification

Findings from the TriMaster trial suggest that stratification of people with type 2 diabetes based on clinical features may help to guide the choice of second- or third-line drug for those who require treatment intensification after metformin.

26-08-2021 | ESC 2021 | Conference coverage | News

Canagliflozin may protect against hyperkalemia in type 2 diabetes with CKD

Canagliflozin may reduce the risk for hyperkalemia, without increasing hypokalemia, in people with type 2 diabetes and chronic kidney disease receiving renin–angiotensin–aldosterone system inhibitors, shows a CREDENCE post-hoc analysis.

22-02-2021 | Canagliflozin | News

Antihypertensive effect for canagliflozin in diabetic renal disease

The SGLT2 inhibitor canagliflozin reduces blood pressure and the need for additional antihypertensives in people with type 2 diabetes and chronic kidney disease, research suggests.

17-12-2020 | Canagliflozin | News

Model demonstrates cost-effectiveness of canagliflozin in type 2 diabetes

Adding canagliflozin to current standard of care improves survival, increases quality-adjusted life–years, and reduces treatment costs for people with type 2 diabetes treated in England over a 10-year period, research suggests.

23-11-2020 | Canagliflozin | News

SGLT2 inhibition may slow decline of advanced diabetic kidney disease

A post-hoc analysis of the CREDENCE trial suggests that canagliflozin could be beneficial in people with advanced diabetic kidney disease.

28-10-2020 | Canagliflozin | News

Canagliflozin linked to reduced anemia risk in people with type 2 diabetes, CKD

Treatment with the SGLT2 inhibitor canagliflozin is associated with a reduced risk for anemia-related outcomes among people with type 2 diabetes and chronic kidney disease, suggests a post-hoc analysis of the CREDENCE trial.

04-09-2020 | Canagliflozin | News

FDA removes amputation Boxed Warning from canagliflozin label

Click through to read more on this announcement

02-09-2020 | Canagliflozin | News

Age, cardiovascular disease impact amputation risk with canagliflozin

Older patients and those with cardiovascular disease are most likely to have an increased risk for lower limb amputation when newly prescribed canagliflozin, relative to a GLP-1 receptor agonist, research shows.

Image Credits